Page 3 - இழப்பீடு குழு ஆஃப் தி பலகை இயக்குநர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cogent Biosciences Announces Creation of Cogent Research Team Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million supports company goals into 2024, including three CGT9486 clinical trials on-track to start this year, beginning with ASM in 1H21 News provided by Share this article Share this article BOULDER, Colo. and CAMBRIDGE, Mass., April 6, 2021 /PRNewswire/  Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the formation of the Cogent Research Team led by newly appointed Chief Scientific Officer, John Robinson, PhD.

United statesUnited kingdomBoulder denverJohn robinsonCompensation committee of the board directorsCogent research teamCogent biosciences incDrug administrationUniversity of delawareIndiana university of pennsylvaniaCogent biosciencesChief scientific officerCogent boardVice presidentArray biopharmaNew drug